# Pharmacogenomics

**Domain:** Health
**Status:** scaffold
**Prediction type:** Drug response and adverse reaction prediction based on an individual's genetic variants affecting drug metabolism, efficacy, and toxicity.

## What This Predicts

For a given drug and individual, this project predicts:
- Likely metabolizer status (poor/intermediate/normal/ultrarapid)
- Risk of serious adverse drug reactions
- Expected efficacy relative to the general population
- Recommended dose adjustments

## Why This Matters

Adverse drug reactions cause ~125,000 deaths annually in the US alone and are a leading cause of hospitalization. Up to 99% of people carry at least one actionable pharmacogenomic variant. This is largely a solved problem scientifically — the barrier is access and implementation.

## Key Drug-Gene Pairs (Initial Focus)

| Gene | Drug Classes Affected |
|------|----------------------|
| CYP2D6 | Antidepressants, opioids, antipsychotics, beta-blockers |
| CYP2C19 | SSRIs, PPIs, clopidogrel (Plavix), antifungals |
| CYP2C9 | Warfarin, NSAIDs, some antiepileptics |
| SLCO1B1 | Statins (simvastatin myopathy risk) |
| TPMT / NUDT15 | Thiopurines (azathioprine, mercaptopurine) |
| HLA-B*57:01 | Abacavir hypersensitivity |
| DPYD | 5-fluorouracil toxicity |
| VKORC1 | Warfarin dose |

## Key Inputs

| Input | Source | Required |
|-------|--------|----------|
| Genetic data (SNP or WGS) | genetic test | yes |
| Drug name or drug class | user input | yes |
| Concurrent medications | user input | optional |
| Kidney/liver function | lab results | optional |

## Output

| Output | Type | Interpretation |
|--------|------|---------------|
| Metabolizer phenotype | categorical | poor/intermediate/normal/ultrarapid |
| Adverse reaction risk | low/medium/high | for specific ADRs |
| Efficacy prediction | categorical | reduced/normal/increased |
| Dosing recommendation | text | adjust dose / avoid / standard |
| Clinical action recommendation | text | references CPIC guidelines |

## Data Sources

- PharmGKB — curated pharmacogenomic knowledge base
- CPIC (Clinical Pharmacogenomics Implementation Consortium) — clinical guidelines
- FDA pharmacogenomics biomarker table
- ClinVar — variant-drug associations
- gnomAD — population allele frequencies by ancestry

## Self-Correction

- **Accuracy metric:** Concordance with CPIC clinical recommendations; adverse event prediction sensitivity
- **Ground truth:** adverse drug reaction reports; clinical outcome data
- **Retraining trigger:** guideline updates from CPIC (we track and incorporate quarterly)

## Refresh Frequency

- Genetic data component: once (genetics don't change)
- Drug-gene interaction database: quarterly (new CPIC guidelines)
- New drugs: on FDA approval of new agents

## Ethical Considerations

- Dosing recommendations must direct users to consult their prescriber — never replace clinical judgment
- Ancestry bias: variant frequencies differ substantially across populations; must disclose accuracy by ancestry group
- Genetic data security is paramount — this data could affect insurability in some jurisdictions
